Compare QFIN & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QFIN | AGIO |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 2018 | 2013 |
| Metric | QFIN | AGIO |
|---|---|---|
| Price | $13.20 | $28.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $32.37 | ★ $37.63 |
| AVG Volume (30 Days) | ★ 1.4M | 642.1K |
| Earning Date | 03-17-2026 | 04-30-2026 |
| Dividend Yield | ★ 11.74% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,011,000.00 |
| Revenue This Year | N/A | $75.68 |
| Revenue Next Year | N/A | $167.63 |
| P/E Ratio | $2.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.68 | $22.24 |
| 52 Week High | $48.94 | $46.00 |
| Indicator | QFIN | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 35.91 | 52.76 |
| Support Level | N/A | $26.48 |
| Resistance Level | $15.46 | $29.49 |
| Average True Range (ATR) | 0.54 | 0.92 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 22.86 | 69.02 |
Qfin Holdings Inc Formerly Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.